4SC AG (4SC)

Oncology Corporate Profile

HQ Location

Am Klopferspitz 19a
82152 Planegg-Martinsried, Germany

Company Description

4SC discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.

Website: http://www.4sc.de/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
resminostat / 4SC-201HDAC inhibitor2nd line metastatic Hepatocellular Carcinoma (HCC)IIYakult
resminostat / 4SC-201HDAC inhibitor3rd line metastatic Hodgkin's LymphomaII
resminostat (+ sorafenib) / 4SC-201 HDAC inhibitorCutaneous T-cell Lymphoma (CTCL)IIYakult
resminostat / 4SC-201HDAC inhibitor2nd line metastatic Colorectal CancerIYakult
4SC-202HDAC inhibitorVarious cancer typesI
4SC-205oral Eg5 kinesin spindle protein inhibitorVarious cancer typesI
4SC-203oral multi-kinase inhibitor selective of FLT3 and VEGFVarious cancer typesIProQinase GmbH

View additional information on product candidates here »

Pipeline image

Source


http://www.4sc.de/

Recent News Headlines

There are no news items to display